610 related articles for article (PubMed ID: 29564837)
21. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.
Majeed A; Ågren A; Holmström M; Bruzelius M; Chaireti R; Odeberg J; Hempel EL; Magnusson M; Frisk T; Schulman S
Blood; 2017 Oct; 130(15):1706-1712. PubMed ID: 28835439
[TBL] [Abstract][Full Text] [Related]
22. Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants.
Dager WE; Roberts AJ; Nishijima DK
Thromb Res; 2019 Jan; 173():71-76. PubMed ID: 30476716
[TBL] [Abstract][Full Text] [Related]
23. Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
Grandhi R; Newman WC; Zhang X; Harrison G; Moran C; Okonkwo DO; Ducruet AF
World Neurosurg; 2015 Dec; 84(6):1956-61. PubMed ID: 26341438
[TBL] [Abstract][Full Text] [Related]
24. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
Rech MA; Masic D; Hammond DA
West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria.
Dev P; Abousaab C; Zhou C; Sarode R
J Thromb Thrombolysis; 2022 Feb; 53(2):249-256. PubMed ID: 34373984
[TBL] [Abstract][Full Text] [Related]
26. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Fixed Versus Weight-Based Prothrombin Complex Concentrate Dosing Strategies for Factor Xa Inhibitor Reversal.
Brett S; Taylor M; Pamela M; Michael G
Clin Appl Thromb Hemost; 2024; 30():10760296241243368. PubMed ID: 38710155
[No Abstract] [Full Text] [Related]
28. Probable pulmonary embolism with repeat administration of prothrombin complex concentrate in a factor Xa inhibitor patient.
King GS; Cottingham LG; Hughes RE; Ratliff PD
J Clin Pharm Ther; 2018 Dec; 43(6):903-905. PubMed ID: 29885249
[TBL] [Abstract][Full Text] [Related]
29. Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis.
Milling TJ; Clark CL; Feronti C; Song SS; Torbati SS; Fermann GJ; Weiss J; Patel D
Am J Emerg Med; 2018 Mar; 36(3):396-402. PubMed ID: 28843518
[TBL] [Abstract][Full Text] [Related]
30. Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.
Mahamad S; Chaudhry H; Nisenbaum R; McFarlan A; Rizoli S; Ackery A; Sholzberg M
J Thromb Thrombolysis; 2019 Feb; 47(2):272-279. PubMed ID: 30506352
[TBL] [Abstract][Full Text] [Related]
31. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
[TBL] [Abstract][Full Text] [Related]
32. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
Connolly SJ; Crowther M; Eikelboom JW; Gibson CM; Curnutte JT; Lawrence JH; Yue P; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Demchuk AM; Pallin DJ; Concha M; Goodman S; Leeds J; Souza S; Siegal DM; Zotova E; Meeks B; Ahmad S; Nakamya J; Milling TJ;
N Engl J Med; 2019 Apr; 380(14):1326-1335. PubMed ID: 30730782
[TBL] [Abstract][Full Text] [Related]
33. Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries.
Cooksey GE; Hamilton LA; McMillen JC; Griffard JH; Rowe AS
Neurocrit Care; 2022 Oct; 37(2):471-478. PubMed ID: 35624388
[TBL] [Abstract][Full Text] [Related]
34. To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban.
Ciccone MM; Zito A; Devito F; Maiello M; Palmiero P
Curr Drug Targets; 2018; 19(6):581-584. PubMed ID: 26424386
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
Terayama Y
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1171-1181. PubMed ID: 28169097
[TBL] [Abstract][Full Text] [Related]
36. [Monitoring options and reversal agents for oral anticoagulants].
Thorup SB; Husted SE; Vang ML
Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096568
[TBL] [Abstract][Full Text] [Related]
37. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
[TBL] [Abstract][Full Text] [Related]
38. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study.
Malec K; Broniatowska E; Undas A
Lupus; 2020 Jan; 29(1):37-44. PubMed ID: 31757182
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
40. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
Levy JH; Moore KT; Neal MD; Schneider D; Marcsisin VS; Ariyawansa J; Weitz JI
J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
